← All trials
NCT06925334
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Apr 13, 2025
- Last posted
- Apr 13, 2025
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tsinghua UniversityLead sponsor
- The Central Hospital of Lishui CityCollaborator
- Tsinghua UniversitySponsor investigator
- Wenzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Jinhua People's HospitalCollaborator
- Tsinghua UniversityOfficial
- Dongyang People's HospitalCollaborator
- Nantong UniversityCollaborator
- Nanchang UniversityCollaborator
- Jinhua Central HospitalCollaborator
- Anhui Medical UniversityCollaborator
- Wuhu City Second People's HospitalCollaborator
- Yiwu Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.